نتایج جستجو برای: fulvestrant

تعداد نتایج: 782  

2014
Yuet-Kin Leung Queeny Kwan-Yi Chan Chi-Fai Ng Fanny Man-Ting Ma Ho-Man Tse Ka-Fai To Jodi Maranchie Shuk-Mei Ho Kin-Mang Lau

Fulvestrant (ICI-182,780) has recently been shown to effectively suppress prostate cancer cell growth in vitro and in vivo. But it is unclear whether microRNAs play a role in regulating oncogene expression in fulvestrant-treated prostate cancer. Here, this study reports hsa-miR-765 as the first fulvestrant-driven, ERβ-regulated miRNA exhibiting significant tumor suppressor activities like fulve...

Journal: :The Lancet. Oncology 2013
Stephen Rd Johnston Lucy S Kilburn Paul Ellis David Dodwell David Cameron Larry Hayward Young-Hyuck Im Jeremy P Braybrooke A Murray Brunt Kwok-Leung Cheung Rema Jyothirmayi Anne Robinson Andrew M Wardley Duncan Wheatley Anthony Howell Gill Coombes Nicole Sergenson Hui-Jung Sin Elizabeth Folkerd Mitch Dowsett Judith M Bliss

BACKGROUND The optimum endocrine treatment for postmenopausal women with advanced hormone-receptor-positive breast cancer that has progressed on non-steroidal aromatase inhibitors (NSAIs) is unclear. The aim of the SoFEA trial was to assess a maximum double endocrine targeting approach with the steroidal anti-oestrogen fulvestrant in combination with continued oestrogen deprivation. METHODS I...

2011
Vineetha Koroth Edavana Xinfeng Yu Ishwori B Dhakal Suzanne Williams Baitang Ning Ian T Cook David Caldwell Charles N Falany Susan Kadlubar

Fulvestrant (Faslodex™) is a pure antiestrogen that is approved to treat hormone receptor-positive metastatic breast cancer in postmenopausal women. Previous studies have demonstrated that fulvestrant metabolism in humans involves cytochromes P450 and UDP-glucuronosyltransferases (UGTs). To date, fulvestrant sulfation has not been characterized. This study examined fulvestrant sulfation with ni...

Journal: :Clinical journal of oncology nursing 2011
Georgia Litsas

Fulvestrant is an estrogen receptor antagonist indicated for the treatment of hormone receptor-positive metastatic breast cancer (MBC) in postmenopausal women with disease progression following antiestrogen therapy. Fulvestrant has a different mechanism of action than other hormonal therapies, including aromatase inhibitors and tamoxifen. In clinical trials of postmenopausal women with MBC, ful...

Journal: :Annals of oncology : official journal of the European Society for Medical Oncology 2010
J M Gasent Blesa V Alberola Candel V Giner Marco V Giner-Bosch M Provencio Pulla J B Laforga Canales

Fulvestrant is a selective estrogen receptor (ER) downregulator; fulvestrant inhibits ER dimerization [1] and reduces ER’s half-life [2]. In preclinical models, fulvestrant inhibited cell growth of the DU145 prostate cancer (PCa) cell line through an ER-b-dependent mechanism [3]. Metastatic PCa expresses ER-b mainly in metastases to the lymph nodes and bones [4]. Androgen receptor (AR) expressi...

2016
Rinath Jeselsohn William T. Barry Ilenia Migliaccio Chiara Biagioni Jin Zhao Jonas De Tribolet-Hardy Cristina Guarducci Martina Bonechi Naomi Laing Eric P.Winer Myles Brown Angelo Di Leo Luca Malorni

Purpose: Fulvestrant is an estrogen receptor (ER) antagonist and an approved treatment for metastatic estrogen receptor–positive (ERþ) breast cancer. With the exception of ER levels, there are no established predictive biomarkers of response to single-agent fulvestrant. We attempted to identify a gene signature of response to fulvestrant in advanced breast cancer. Experimental Design: Primary t...

2011
Yuki Ishii Luena Papa Urvashi Bahadur Zhenyu Yue Julio Aguirre-Ghiso Toshi Shioda Doris Germain

Purpose: Fulvestrant is known to promote the degradation of the estrogen receptor (ER) in the nucleus. However, fulvestrant also promotes the aggregation of the newly synthesized ER in the cytoplasm. Accumulation of protein aggregates leads to cell death but this effect is limited as a result of their elimination by the proteasome. We tested whether combining fulvestrant with the proteasome inh...

2013
Lijiang Zhang Jiajun Cui Marissa Leonard Kenneth Nephew Yongquan Li Xiaoting Zhang

Pure anti-estrogen fulvestrant has been shown to be a promising ER antagonist for locally advanced and metastatic breast cancer. Unfortunately, a significant proportion of patients developed resistance to this type of endocrine therapy but the molecular mechanisms governing cellular responsiveness to this agent remain poorly understood. Here, we've reported that knockdown of estrogen receptor c...

Journal: :Clinical cancer research : an official journal of the American Association for Cancer Research 2016
Rinath Jeselsohn William T Barry Ilenia Migliaccio Chiara Biagioni Jin Zhao Jonas De Tribolet-Hardy Cristina Guarducci Martina Bonechi Naomi Laing Eric P Winer Myles Brown Angelo Di Leo Luca Malorni

PURPOSE Fulvestrant is an estrogen receptor (ER) antagonist and an approved treatment for metastatic estrogen receptor-positive (ER+) breast cancer. With the exception of ER levels, there are no established predictive biomarkers of response to single-agent fulvestrant. We attempted to identify a gene signature of response to fulvestrant in advanced breast cancer. EXPERIMENTAL DESIGN Primary t...

2017
Qing Chen Ziyi Weng Yunshu Lu Yijun Jia Longlong Ding Fang Bai Meixin Ge Qing Lin Kejin Wu

PURPOSE To investigate the effects of trastuzumab (herceptin) and fulvestrant (falsodex) either in combination or alone, on downstream cell signaling pathways in lab-cultured human HR+/HER2+ breast cancer cell lines ZR-75-1 and BT-474, as well as on protein expression levels in mouse xenograft tissue. METHODS Cells were cultivated in the presence of trastuzumab or fulvestrant or both. Molecul...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید